• TNI BioTech Products

    IRT-101 is an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells
    +Read More
  • Our Approach

    The purpose of TNI BioTech's immunotherapy is to increase the production of the immune system by increasing production of DC cells...
    +Read More
  • Business Development

    TNI BioTech has acquired a number of patents and is in planning on the commercialization of our patented technology.
    +Read More
  • 1
  • 2
  • 3
Follow Us

Company Overview

At TNI BioTech, Inc., our goal is to benefit patients with chronic and often life-threatening diseases through the activation and rebalancing of the body's immune system using our patented immunotherapy.

Our products, technologies, and patents are designed to harness the power of the immune system to improve the treatment of cancer and infections, such as HIV/AIDS and autoimmune diseases. We are currently developing active and adoptive forms of immunotherapies.

Our most advanced clinical programs involve immunotherapy with methionine-enkephalin (MENK) or low dose naltrexone, which both work by triggering opioid receptors on immune cells and lead to an activation and expansion of various cells in the immune system.

OneMedPlace Management Interview: Noreen McGurrin Griffin, CEO of TNI Biotech

IRT-101

IRT-101

 is an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells.

Read More

IRT-102

IRT-102 

is an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells and following an enriching external incubation...

Read More

IRT-103

IRT- 103 

is an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.

Read More

Latest News

Enkephalins--enhancement of active T-cell rosettes from lymphoma patients.

Mar 26 1983

Clin Immunol Immunopathol. 1983 Mar;26(3):446-51.

Enkephalins--enhancement of active T-cell rosettes from lymphoma patients.
Miller GC, Murgo AJ, Plotnikoff NP.


Abstract

Methionine enkephalin was found to increase significantly the active T-cell rosettes from lymphoma patients. In sharp contrast, the leucine enkephalin was observed to increase active rosettes only at a single low concentration. Neither enkephalin significantly altered the total T-cell rosettes. It is suggested that methionine enkephalin could have a significant influence in enhancing cell-mediated immunity and T-cell function, particularly in lymphoma patients